Total funding raised Dec 2022
Total Funding Raised - 1.3M€
CancerAppy closed 2022 with €1.3M total raised.
CA05 Lead Identification
CA05 - Lead Identification
We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.
CA04 Antidoby vs Pancreatic cancer
CA04 - Antidody against pancreatic cancer
We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer.
CA02/03 Target Identification vs NSCLC
CA02/03 - Target Identification
CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies
Total Funding Raised
Total Funding Raised - 690K
CancerAppy closed 2021 with €690K total raised.